Lemaitre Vascular Intrinsic Stock Value – Lemaitre Vascular Reports 19% Year-Over-Year Increase in Revenue for Q2 2023
August 10, 2023
☀️Earnings Overview
For the quarter ending June 30 2023, LEMAITRE VASCULAR ($NASDAQ:LMAT) saw revenue of USD 50.1 million, representing an increase of 19.0% compared to the corresponding period in FY2022. Net income for the same quarter also surged by 130.1%, reaching USD 8.1 million.
Analysis – Lemaitre Vascular Intrinsic Stock Value
GoodWhale has conducted an analysis of the fundamentals of LEMAITRE VASCULAR. Our proprietary Valuation Line has revealed that the intrinsic value per share of LEMAITRE VASCULAR is around $54.2. This means that currently, LEMAITRE VASCULAR stock is traded at $62.8, which is a fair price but slightly overvalued by 15.8%. Investors should take this into consideration when making decisions regarding their investments in the company. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lemaitre Vascular. More…
| Total Revenues | Net Income | Net Margin |
| 177.17 | 25.22 | 14.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lemaitre Vascular. More…
| Operations | Investing | Financing |
| 22.95 | -10.37 | -9.23 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lemaitre Vascular. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 326.47 | 42.64 | 12.81 |
Key Ratios Snapshot
Some of the financial key ratios for Lemaitre Vascular are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.6% | 15.5% | 17.9% |
| FCF Margin | ROE | ROA |
| 10.2% | 7.1% | 6.1% |
Peers
It focuses on the development, manufacture and marketing of minimally invasive products for the treatment of peripheral vascular diseases. The company operates through two segments, Direct and OEM. The Direct segment offers proprietary products to hospitals and other medical institutions through direct sales force. The OEM segment provides stents and other products to Original Equipment Manufacturers (OEMs) for sale under their own brands. LeMaitre’s competitors include Atrion Corp, Implanet SA, Vycor Medical Inc.
– Atrion Corp ($NASDAQ:ATRI)
Atrion Corporation is a medical device company that develops, manufactures and markets products primarily for use in cardiac and ophthalmic surgery. The company’s products include Cardiax, a cannula used in cardiac surgery; Ophthalmic products, including the HydroVue and Glaucoma Shunt systems to treat glaucoma; and PerQCat, a catheter used in urology procedures.
– Implanet SA ($OTCPK:IMPZY)
Implanet SA is a French company specializing in the design and manufacture of medical implants for the treatment of orthopedic pathologies. The company’s products are used in the treatment of various conditions, including osteoarthritis, degenerative disc disease, scoliosis, and deformities of the hip, knee, and shoulder. As of 2022, Implanet SA had a market capitalization of 3.88 million euros and a return on equity of -114.56%. The company’s products are sold in over 50 countries worldwide and its customers include some of the world’s leading orthopedic surgeons and hospitals.
– Vycor Medical Inc ($OTCPK:VYCO)
Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for neurosurgery. The company’s products are designed to provide surgeons with improved access and visualization during surgery, while minimizing tissue damage and surgical time. Vycor Medical’s products are sold in over 30 countries worldwide.
As of 2022, Vycor Medical Inc had a market capitalization of 3.17 million and a return on equity of 6.36%. The company’s products are used in a variety of neurosurgical procedures, including brain surgery, spinal surgery, and skull-base surgery.
Summary
Investors should take note of the strong financial results released by LEMAITRE VASCULAR for the quarter ended June 30 2023. Revenue rose 19.0% year-over-year to USD 50.1 million, with net income more than doubling to USD 8.1 million. This growth was primarily driven by increased demand for the company’s products and services, which has helped it maintain a competitive edge in the market. With its strong financial position, LEMAITRE VASCULAR appears to be well positioned to capitalize on future opportunities and continue producing positive results.
Related Posts
Recent Posts
